Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Femke van den Ham"'
Autor:
Judith Wienke, Maaike Nederend, Jeanette Leusen, Marjolein Stip, Marco Jansen, Chilam Chan, Femke van den Ham, Geert van Tetering, Elsemieke Passchier
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Background Approximately half of the neuroblastoma patients develop high-risk neuroblastoma. Current treatment involves a multimodal strategy, including immunotherapy with dinutuximab (IgG ch14.18) targeting GD2. Despite achieving promising results,
Externí odkaz:
https://doaj.org/article/b79a80b51faa484288067e852353cc9d
Autor:
Emma M. de Koff, Debbie van Baarle, Marlies A. van Houten, Marta Reyman, Guy A. M. Berbers, Femke van den Ham, Mei Ling J. N. Chu, Elisabeth A. M. Sanders, Debby Bogaert, Susana Fuentes
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
The establishment and composition of the host microbiota is known to impact the function of the host immune response. Here the authors show that mode of delivery may impact the intestinal microbiota composition from birth and modulate the response to
Externí odkaz:
https://doaj.org/article/ecd59ead9c2f43d5a832cfcfae8fb152
Autor:
Judith Wienke, S Nierkens, Miranda P Dierselhuis, Jan J Molenaar, Annelisa M Cornel, Ester Dunnebach, Damon A Hofman, Sanjukta Das, Satyaki Sengupta, Femke van den Ham, Josephine G M Strijker, Denise A M H van den Beemt, Anke H W Essing, Bianca Koopmans, Sem A G Engels, Vania Lo Presti, Celina S Szanto, Rani E George, Sebastiaan van Heesch
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Background Immunotherapy in high-risk neuroblastoma (HR-NBL) does not live up to its full potential due to inadequate (adaptive) immune engagement caused by the extensive immunomodulatory capacity of HR-NBL. We aimed to tackle one of the most notable
Externí odkaz:
https://doaj.org/article/7142ba69053342a98bcc3622acf2b968
Autor:
Judith Wienke, Lindy L. Visser, Waleed M. Kholosy, Kaylee M. Keller, Marta Barisa, Sophie Munnings-Tomes, Elizabeth Carlton, Evon Poon, Ana Rodriguez, Ronald Bernardi, Femke van den Ham, Sander R. van Hooff, Yvette A.H. Matser, Michelle L. Tas, Karin P.S. Langenberg, Philip Lijnzaad, Josephine G.M. Strijker, Alvaro Sanchez-Bernabeu, Annelisa M. Cornel, Frank C.P. Holstege, Juliet Gray, Lieve A.M. Tytgat, Ronald R. de Krijger, Marijn A. Scheijde-Vermeulen, Marc H.W.A. Wijnen, Miranda Dierselhuis, Karin Straathof, Sam Behjati, Wei Wu, Albert J.R. Heck, Jan Koster, Stefan Nierkens, Louis Chesler, John Anderson, Hubert N. Caron, Thanasis Margaritis, Max M. van Noesel, Jan J. Molenaar
Pediatric patients with high-risk neuroblastoma have poor survival rates and urgently need more effective treatment options with less side effects. As novel and improved immunotherapies may fill this need, we dissected the immunoregulatory interactio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25012e4e18c571cc6fe4704c0cf8a9ab
https://doi.org/10.1101/2022.07.15.499859
https://doi.org/10.1101/2022.07.15.499859
Autor:
Annelisa M Cornel, Ester Dunnebach, Damon A Hofman, Sanjukta Das, Satyaki Sengupta, Femke van den Ham, Judith Wienke, Josephine G M Strijker, Denise A M H van den Beemt, Anke H W Essing, Bianca Koopmans, Sem A G Engels, Vania Lo Presti, Celina S Szanto, Rani E George, Jan J Molenaar, Sebastiaan van Heesch, Miranda P Dierselhuis, S Nierkens
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e005002
BackgroundImmunotherapy in high-risk neuroblastoma (HR-NBL) does not live up to its full potential due to inadequate (adaptive) immune engagement caused by the extensive immunomodulatory capacity of HR-NBL. We aimed to tackle one of the most notable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::523204a6719fb30ea68604533c303a61
https://doi.org/10.1136/jitc-2022-005002
https://doi.org/10.1136/jitc-2022-005002